nursing-care-2019-posters-abstracts

6 / 14

allied
academies
Page 37
Notes:
May 23-24, 2019 | Vienna, Austria
Nursing Care
28th International Conference on
Journal of Intensive and Critical Care Nursing | Volume 2
J Intensive Crit Care Nurs, Volume 2
Selective and immunomodulating properties of the anticancer proton preparation
NSC-631570 (Ukrain)
Wassil Nowicky
Ukranian Anticancer Institute, Austria
One of the most significant problems of cancer therapy
is the damaging activity of anticancer drugs against
normal body cells. All attempts to develop a therapeutic
agent with a selective cytotoxic effect on tumor cells had
no much success because of the high degree of biological
identity between healthy and malignant cells. The celandine
is being used in the medicine over more than 3500 years.
The first data concerning the therapeutic effect of the juice
of celandine in the patient with malignant melanoma were
published in Germany in 1536. From that time drugs based
on biologically active substances of celandine are widely
used to treat cancer and non-cancer disease. It is well known
that tumor cell is more negatively charged as compared to
normal cell. We have used this feature of the tumor cell to
give NSC-631570 a property to selectively interact with it,
without endangering healthy cells and tissues. The drug is
strongly positively charged. Due to this it has an ability to be
selectively accumulated in tumor tissue and to induce tumor
cell apoptosis only in tumor cells without harmful effect on
normal cells. Potent selective antitumor effect of NSC-631570
repeatedly proven by the results of clinical trials. There is an
assumption that the same high selective cytotoxicity of drug
on tumor cells of different origin is the result of its interaction
with a ubiquitous tumor-specific (or overexpressed in tumor
cells) compound involved in the induction of cell death. It
remains to find this compound.
Speaker Biography
Wassil Nowicky — Dipl. Ing., Dr. techn., DDDr. h. c., Director of “Nowicky
Pharma” and President of the Ukrainian Anti-Cancer Institute (Vienna,
Austria). Has finished his study at the Radiotechnical Faculty of the
Technical University of Lviv (Ukraine) with the end of 1955 with graduation
to “Diplomingeniueur” in 1960 which title was nostrificated in Austria in
1975.Dr.WassilNowickybecametheveryfirstscientist inthedevelopment
of the anticancer protonic therapy and is the inventor of the preparation
against cancer with a selective effect on basis of celandine alkaloids
“NSC-631570”. He used the factor that cancer cells are more negative
charged than normal cells and invented the Celandine alkaloid with a
positive charge thanks to which it accumulates in cancer cells very fast.
Thus, he is invited as an Honorable Speaker to take part in many scientific
international congresses and conferences in USA, Australia, Japan, UAE,
Europe. Author of over 300 scientific articles dedicated to cancer research.
He is a real member of the New York Academy of Sciences, member of the
European Union for applied immunology and of the American Association
for scientific progress, honorary doctor of the Janka Kupala University in
Hrodno, doctor “honoris causa” of the Open international university on
complex medicine in Colombo, honorary member of the Austrian Society
of a name od Albert Schweizer. He has received the award for merits of
National guild of pharmasists of America. the award of Austrian Society of
sanitary, hygiene and public health services and others.
e: